Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CytRx Reports Update For Phase 2 Leukemia Trial With Tamibarotene
CytRx has provided a favorable progress update for its ongoing Phase 2 STAR-1 registration clinical trial, to evaluate the efficacy and safety of orally administered tamibarotene as a
CytRx has provided a favorable progress update for its ongoing Phase 2 STAR-1 registration clinical trial, to evaluate the efficacy and safety of orally administered tamibarotene as a
Yaupon has completed enrollment for a pivotal phase-II clinical trial for Clearazide, for the treatment of early-stage cutaneous T-cell lymphoma (CTCL – stages 1-2a). The randomized, double-blind, controlled
Achillion has initiated dosing in a phase-I clinical trial of ACH-1625, a protease inhibitor for the treatment of hepatitis-C virus (HCV) infection. ACH-1625 is a strong small molecule
AcelRx has reported positive results from the second phase-II clinical study evaluating the safety and efficacy of its ARX-01 Sufentanil NanoTabs. It is to be used for the
Palkion has initiated preclinical development studies for orally available anemia therapeutic candidate, that modulates the Hypoxia-Inducible factor Prolyl Hydroxylase (HIF-PH) enzyme system. CrystalGenomics would use its structure-based drug
Sinovac has received a revised Drug Supplementary Application Approval (SAA) for Panflu, company’s pandemic influenza vaccine, from SFDA, based on the phase-IIb clinical trial. Under the revised approval,
AMAG Pharmaceuticals has announced that it has not received an action letter from FDA for Feraheme (ferumoxytol) Injection, for the treatment of iron deficiency anemia in adult chronic
VITAS has signed an agreement with UniCare, which will provide UniCare members access to hospice services in every market in which VITAS operates. Tim O’Toole, Chief Executive Officer
Results from the one-year extension of a pivotal Eslicarbazepine Acetate phase III study showed that add-on treatment with once-daily anti-epileptic Zebinix (eslicarbazepine acetate; ESL), resulted in a sustained
Mylan has collaborated with Biocon on the development, manufacturing, supply and commercialization of multiple, high-value generic biologic compounds for the global marketplace. As part of the collaboration, Mylan